Formulation And Evaluation Of Muchoadesive Buccle Tablet For Diabetis Using Neteglinide

Abstract

Mucoadhesive Buccal Tablets Of Nateglinide Were Formulated And Evaluated To Enhance Drug Bioavailability, Provide Controlled Drug Release, And Improve Patient Compliance In Diabetes Management. Buccal Drug Delivery Bypasses Hepatic First-pass Metabolism, Potentially Increasing The Drug's Bioavailability While Ensuring Sustained Therapeutic Action. In This Study, Various Bioadhesive Polymers, Including Hydroxypropyl Methylcellulose (HPMC), Carbopol 934, And Sodium Carboxymethylcellulose (Sodium CMC), Were Used To Optimize The Mucoadhesive Properties And Drug Release Profile Of The Tablets. The Tablets Were Prepared Using The Direct Compression Method And Subjected To A Comprehensive Set Of Physicochemical And In-vitro Evaluation Tests, Including Weight Variation, Hardness, Swelling Index, Surface PH, Mucoadhesive Strength, Drug Content Uniformity, And In-vitro Drug Release Studies. The Optimized Formulation Demonstrated Satisfactory Mucoadhesive Strength, Appropriate Swelling Behavior, And A Controlled Drug Release Profile Over An Extended Period. These Results Indicate That Buccal Delivery Of Nateglinide Could Be A Promising Alternative To Conventional Oral Formulations, Potentially Reducing The Frequency Of Administration And Enhancing Therapeutic Outcomes For Diabetic Patients. Further Studies, Including In-vivo Pharmacokinetic And Pharmacodynamic Evaluations, Are Necessary To Validate The Efficacy Of This Novel Drug Delivery System.

Keywords